Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.52 |
| ▸ | GLS | O94925 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 9/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27440203 | 0.89 | GLS (0.49) | GLSAOC3HTR2CSLC6A4RIPK1 | |
| SCHEMBL2318201 | 0.86 | ACHE (0.41) | ACHEGLSHTR2CSLC6A4RIPK1 | |
| SCHEMBL1831339 | 0.85 | GLS (0.50) | GLSAOC3HTR2CSLC6A4RIPK1 | |
| SCHEMBL7021352 | 0.85 | GLS (0.53) | GLSAOC3HTR2CSLC6A4RIPK1 | |
| SCHEMBL14558956 | 0.84 | GLS (0.51) | GLSAOC3HTR2CSLC6A4RIPK1 | |
| SCHEMBL2228851 | 0.83 | HSD11B1 (0.51) | GLSAOC3HTR2CSLC6A4RIPK1 | |
| SCHEMBL14987121 | 0.82 | GLS (0.56) | GLSAOC3HTR2CSLC6A4RIPK1 | |
| SCHEMBL30264842 | 0.82 | HSP90AA1 (0.49) | ACHEGLSAOC3HTR2CSLC6A4 | |
| SCHEMBL14426297 | 0.82 | HSP90AA1 (0.49) | ACHEGLSAOC3HTR2CSLC6A4 | |
| SCHEMBL16942777 | 0.82 | HSD17B2 (0.53) | GLSHTR2CSLC6A4RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118561841-A | Novel aryl-pyrido-pyrimidin-one derivatives | 豪夫迈·罗氏有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20230322776-A1 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322776-A1 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-10-12 | — | — | US | disclosed |
| CN-116710451-A | Novel aryl-pyrido-pyrimidin-one derivatives | 豪夫迈·罗氏有限公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2022129260-A1 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-23 | — | — | WO | disclosed |
| EP-0997474-B1 | Antithrombotic agents | PFIZER (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6417203-B1 | HETEROCYCLIC AMIDES | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-6180627-B1 | INDOLE, INDAZOLE, BENZOTRIAZOLE AND BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2001-01-30 | — | — | US | disclosed |
| EP-0997474-A1 | Antithrombotic agents | PFIZER INC. (US) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322776-A1 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | QDPR, P2RY1, REN | ACHE 2533/4885GLS 645/4885AOC3 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.